The Trial Steering Committee (TSC) is responsible for oversight of the trial in order to safeguard the interests of trial patients.
The Trial Steering Committee (TSC) is responsible for oversight of the trial in order to safeguard the interests of trial patients.
The Trial Steering Committee (TSC) is responsible for oversight of the trial in order to safeguard the interests of trial patients. The TSC is comprised of a 75% majority of independent and lay members, as well as the Chief Investigator, representatives of Principal Investigators, a representative of the sponsor, the health economist and senior trial statistician. The committee provides advice to the Chief Investigator, UCL Comprehensive Clinical Trials Unit, the funder and sponsor on all aspects of the trial through its Independent Chair. The remit of the TSC is to oversee study conduct and advise the TMG.
The Trial Management Group (TMG) co-ordinates and strategically manages the trial.
The Independent Data Monitoring Committee (IDMC) is the only oversight body that has access to un-blinded accumulating comparative data. The IDMC is responsible for safeguarding the interests of trial patients, monitoring the accumulating data and making recommendations to the TSC on whether the trial should continue as planned.
The Trial Management Group (TMG) co-ordinates and strategically manages the trial.
The Trial Management Group (TMG) co-ordinates and strategically manages the trial.
The Trial Management Group is responsible for the day-to-day management of the trial, including monitoring of all aspects of the conduct and progress of the trial, ensuring that the protocol is adhered to and taking appropriate action to safeguard participants and the quality of the trial itself.
The Trial Steering Committee (TSC) is responsible for oversight of the trial in order to safeguard the interests of trial patients. The TSC is comprised of a 75% majority of independent and lay members, as well as the Chief Investigator, representatives of Principal Investigators, a representative of the sponsor, the health economist and senior trial statistician. The committee provides advice to the Chief Investigator, UCL Comprehensive Clinical Trials Unit, the funder and sponsor on all aspects of the trial through its Independent Chair. The remit of the TSC is to oversee study conduct and advise the TMG.
The IDMC is responsible for safeguarding the interests of trial patients, monitoring the accumulating data and making recommendations to the TSC on whether the trial should continue as planned.
The IDMC is responsible for safeguarding the interests of trial patients, monitoring the accumulating data and making recommendations to the TSC on whether the trial should continue as planned.
The Independent Data Monitoring Committee (IDMC) is the only oversight body that has access to un-blinded accumulating comparative data. The role of the IDMC is to assess at intervals, the progress of the trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop the trial.
Clinical Senior Lecturer in Trauma and Orthopaedics, Consultant Orthopaedic Foot and Ankle Surgeon
Mr Goldberg OBE qualified from St Mary’s Hospital Medical School (Imperial College London) in 1994. He is the Chief Investigator on the TARVA trial.
Read more